TriangleNT-I7 for large B-cell lymphoma (NCT07052305)
NT-I7 for large B-cell lymphoma trial for Large B-cell Lymphoma (NCT07052305). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for large B-cell lymphoma that has returned or not responded, in patients who receive standard CAR T therapy.
The idea: help the CAR T cells last. NT-I7 is a long-acting form of interleukin-7, a protein that supports T cell growth. Patients receive two injections into the muscle, around day 10 and day 31 after the CAR T infusion. The hypothesis is that NT-I7 may help the cells expand and persist.
The first question is whether it is safe and tolerable. At Washington University in St. Louis, Zachary Crees leads this early study.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.